HUTCHMED (China) Limited (HCM) RNS Announcements

Add to Alert list
Date Time Source Announcement
14 Dec 2021 07:00 AM
RNS
HMPL-523 Clinical Data Presented at ASH
10 Dec 2021 10:00 AM
RNS
HUTCHMED Presents Data at ESMO Immuno-Oncology '21
06 Dec 2021 07:00 AM
RNS
HUTCHMED Completes Planned Enrollment of FRESCO-2
03 Dec 2021 07:00 AM
RNS
Updated NRDL to include ELUNATE and SULANDA
30 Nov 2021 08:30 AM
RNS
Total Voting Rights
24 Nov 2021 07:00 AM
RNS
HUTCHMED and AZ Initiate SACHI Phase 3 Trial
08 Nov 2021 07:00 AM
RNS
HUTCHMED to Present Clinical Data at ASH
01 Nov 2021 07:00 AM
RNS
HUTCHMED and AZ Initiate SAMETA Global P3 Trial
29 Oct 2021 09:30 AM
RNS
Total Voting Rights
28 Oct 2021 07:00 AM
RNS
HUTCHMED Initiates Phase III Trial of HMPL-523
20 Oct 2021 09:30 AM
RNS
Grant of Awards under Long Term Incentive Plan
30 Sep 2021 09:30 AM
RNS
Total Voting Rights
29 Sep 2021 07:00 AM
RNS
Closure of Non-Core OTC Joint Venture Divestment
29 Sep 2021 07:00 AM
RNS
HUTCHMED Highlights Presentations at CSCO 2021
21 Sep 2021 07:00 AM
RNS
HUTCHMED Initiates Phase III Trial SURTORI-01
20 Sep 2021 07:00 AM
RNS
Japan Bridging Study For Surufatinib Initiated
13 Sep 2021 07:00 AM
RNS
Breakthrough Therapy Designation for Amdizalisib
08 Sep 2021 11:30 AM
RNS
HUTCHMED and AZ Initiate Phase III Trial in China
07 Sep 2021 09:30 AM
RNS
HUTCHMED to Present Clinical Data at ESMO
06 Sep 2021 07:00 AM
RNS
HUTCHMED Shares Included in Stock Connect Programs
02 Sep 2021 12:45 PM
RNS
Grant of Share Options, and Awards under LTIP
31 Aug 2021 09:30 AM
RNS
Total Voting Rights
26 Aug 2021 07:00 AM
RNS
Phase Ib/II Trial of Fruquintinib & Tislelizumab
23 Aug 2021 07:00 AM
RNS
HUTCHMED Selected for Certain Hang Seng Indexes
17 Aug 2021 09:30 AM
RNS
ELECTRONIC COMMUNICATION OF CORPORATE INFORMATION
09 Aug 2021 07:00 AM
RNS
HUTCHMED & Epizyme Announce TAZVERIK Collaboration
30 Jul 2021 09:30 AM
RNS
Total Voting Rights
28 Jul 2021 12:00 PM
RNS
Interim Results and Business Updates
28 Jul 2021 07:00 AM
RNS
Phase II Trial of ORPATHYS Initiated
23 Jul 2021 12:01 PM
RNS
Stabilizing Actions & End of Stabilization Period
16 Jul 2021 10:50 AM
RNS
Holding(s) in Company
16 Jul 2021 07:00 AM
RNS
Surufatinib MAA Submitted and Validated by the EMA
14 Jul 2021 09:35 AM
RNS
Holding(s) in Company
13 Jul 2021 07:00 AM
RNS
First Commercial Sale of ORPATHYS® in China
12 Jul 2021 02:35 PM
RNS
Full Exercise of the Over-allotment Option
06 Jul 2021 09:30 AM
RNS
HUTCHMED Initiates Phase I Trials of HMPL-295
02 Jul 2021 11:15 AM
RNS
Holding(s) in Company
02 Jul 2021 09:30 AM
RNS
Notice of Results
01 Jul 2021 11:00 AM
RNS
US FDA Accepts NDA Filing for Surufatinib
30 Jun 2021 10:02 AM
RNS
Holdings in Company
30 Jun 2021 10:01 AM
RNS
Total Voting Rights
30 Jun 2021 10:00 AM
RNS
Closing of Global Offering and Hong Kong Listing
29 Jun 2021 07:00 AM
RNS
Blocklisting Six Monthly Return
23 Jun 2021 03:21 PM
RNS
HUTCHMED Announces Pricing of Global Offering
22 Jun 2021 06:22 PM
RNS
Savolitinib approved in China for lung cancer
18 Jun 2021 04:05 PM
RNS
HUTCHMED Announces NMPA Approval of Surufatinib
18 Jun 2021 07:01 AM
RNS
HUTCHMED Launches Hong Kong IPO
18 Jun 2021 07:00 AM
RNS
Disclosure Update
20 May 2021 07:00 AM
RNS
Clinical Data to be Presented at ASCO21
17 May 2021 07:00 AM
RNS
HUTCHMED to Host Company Update

Hutchmed China  Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) is headquartered in Hong Kong and markets its products worldwide.

It was founded in 2000 and listed in London in 2018 under the ticker HCM. 

UK 100

Latest directors dealings